Board of Directors

Harry OllilaHarry Ollila, MSc (Engineering)
Chairman of the Board of Directors

Mr. Ollila is Chairman of the Board of BonAlive Biomaterials Ltd. Previously Mr. Ollila held the position of executive vice president at Konecranes Plc and he was a member of the Executive Board between 1994 and 2011. Earlier, from 1972 to 1991, Mr. Ollila worked for Ahlstrom Corporation.

Fredrik OllilaFredrik Ollila, PhD (Biochemistry)
Chief Executive Officer
Member of the Board of Directors

Dr. Ollila has a cross-functional background. He obtained his doctorate in biochemistry from Åbo Akademi University, Finland and has also studied Marketing and Finance at the Business School in Turku, Finland. Between 2003 and 2006 he held several positions at Novartis Pharma AG in Basel, Switzerland with increasing levels of responsibility. Dr. Ollila managed the FiberLive technology at Vivoxid Ltd. Between 2006 and 2008, and from March 2008 he was responsible for the global sales and marketing of BonAlive® at Vivoxid Ltd. Dr. Ollila was the key architect in executing the management buy-out of the
BonAlive® technology from Vivoxid Ltd.

Fredrik OllilaJimmy Lucchesi, BSc (Engineering)
Deputy member of the Board of Directors

Mr. Lucchesi has served three life science companies for the last 10 years in managerial positions and during that period he has gained comprehensive knowledge of design development, business development and manufacturing of medical devices. Prior to this, Mr. Lucchesi worked as a research scientist at the University of Helsinki. He was employed by Vivoxid in 2006 as Business Development Manager and joined the newly formed company BonAlive Biomaterials Ltd in 2010.




Janek Frantzén, MD, PhD (Consultant Neurosurgeon)
Janek FrantzénMember of the Board of Directors

Dr. Frantzén completed his medical studies at the University of Bergen, Norway in 2001. He then continued residency in neurosurgery atTurku University, Finland and partly at Karolinska University Hospital, Sweden. After completing his residency in 2008 he receiveda Fulbright scholar in 2010 enabling a clinical fellowship at Jackson Memorial Hospital, University of Miami. Dr. Frantzén defended his Ph.D. thesis investigating the use of bioactive glass in spine surgery in September 2012 at the University of Turku, Finland. Dr. Frantzén has extensive experience in the clinical use, and also in the experimental use of bioactive glass and other biomaterials. He is also involved in ongoing pre-clinical and clinical research projects within the field of biomaterials and works as a consultant for medical companies besides his clinical work at Helsinki University Central Hospital and NEO Hospital, Turku.